NASDAQ · Key Statistics

Prelude Therapeutics Incorporated (PRLD) P/E Ratio, ROE & Key Statistics

$3.30 NASDAQ: PRLD Market Cap $190.71M

Data as of Nov 17, 2026 (intraday, delayed) · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Prelude Therapeutics Incorporated (PRLD), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-5.25
P/B ratioShare price divided by book value per share.2.83
P/S ratioMarket value divided by annual revenue.9.15
PEG ratioP/E divided by the earnings growth rate.-0.06
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-3.56
EV / RevenueEnterprise value against annual revenue.8.88
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-19.05%
Free cash flow yieldFree cash flow as a percentage of market value.-14.16%
Price / free cash flowMarket value divided by free cash flow.-7.06

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.72.01%
Operating marginRevenue left after operating costs.-283.92%
Net marginRevenue left after every cost, including tax and interest.-247.12%
Return on equityProfit as a percentage of shareholders’ equity.-55.14%
Return on assetsProfit as a percentage of total assets.-30.38%
Return on capital employedOperating profit against the capital the business uses.-43.27%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.4.20
Quick ratioThe same, excluding inventory.4.20
Cash ratioCash alone against current liabilities.0.66
Debt to equityTotal borrowings against shareholders’ equity.0.14
Debt to assetsTotal borrowings against total assets.0.13
Interest coverageHow many times operating profit covers the interest bill.0.00

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$1.29
Book value per shareShareholders’ equity divided by shares outstanding.$1.20
Market capitalisationShare price times shares outstanding.$190.71M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$192.37M
EmployeesReported headcount.131

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Prelude Therapeutics Incorporated (PRLD) statistics — frequently asked questions

What is Prelude Therapeutics Incorporated's P/E ratio?

Prelude Therapeutics Incorporated (PRLD) trades on a price-to-earnings ratio of -5.25. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Prelude Therapeutics Incorporated's return on equity?

Prelude Therapeutics Incorporated (PRLD) reports a return on equity of -55.14%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Prelude Therapeutics Incorporated carry?

Prelude Therapeutics Incorporated (PRLD) has a debt-to-equity ratio of 0.14, which compares total borrowings with shareholders' equity.

What is Prelude Therapeutics Incorporated's profit margin?

Prelude Therapeutics Incorporated (PRLD) keeps -247.12% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.